medigraphic.com
Instituto Nacional de Salud Pública

2004, Number 4

<< Back Next >>

salud publica mex 2004; 46 (4)

El factor de crecimiento transformanteβ como blanco terapéutico

Gálvez-Gastélum FJ, Sandoval-Rodríguez AS, Armendáriz-Borunda J

Language: Spanish
References: 81
Page: 341-350
PDF size: 173.87 Kb.


ABSTRACT

Transforming growth factor-β (TGF-β family members include TGF-β, activins, and bone morphogenetic proteins (BMP). These proteins are structurally related cytokines secreted in diverse Metazoans.TGF-β family members regulate cellular functions such as proliferation, apoptosis, differentiation, and migration, and play an important role in organism development. Deregulated TGF-β family signaling participates in various human pathologies including autoimmune diseases, vascular disorders, fibrotic disease, and cancer. Ligand-induced activation ofTGF-β family receptors with intrinsic serine/threonine kinase activity, triggers phosphorylation of the intracellular effectors of TGF-β signaling, the Smads proteins. Once these proteins are activated they translocate into the nucleus, where they induce transcription of target genes and regulate cellular processes and functions. Novel therapeutic strategies are currently being developed to correct alterations in pathologies that involve TGF-β as the main mediator.


REFERENCES

  1. Blobe G, Schiemman W, Lodish H. Role of transforming growth factor B in human disease. N Engl J Med 2000;4:1350-1358.

  2. Zhu H, Burgess A. Regulation of transforming growth factor B signaling. Mol Cell Biol Res Community 2001;4:321-330.

  3. Miyazono K. Positive and negative regulation ofTGF/3 signaling.J Cell Sci 2000;1 13:1 101-1 109.

  4. Peralta-Zaragoza O, Lagunas-Martínez A, Madrid-Marina V. Transforming growth factor beta-1: Structure, function, and regulation mechanisms in cancer. Salud Publica Mex 2001;43:340-351.salud pública de méxico / vol.46, no.4, julio-agosto de 2004

  5. Border W, Noble N.TGF-/3. Sci Am Sci Med 1995;2:68-77.

  6. Bissell M, Roulot D, George J.Transforming growth factor and the liver. Hepatology 2001;34:859-867.

  7. Hernández-Cañaveral I, González J, López-Casillas F,Armendáriz-Borunda J. Amplified expression of dominant-negative transforming growth factor-beta type 11 receptor inhibits collagen type 1 production via reduced Smad-3 activity.J Gastroenterol Hepatol 2004;19:380-387.

  8. Caestecker M.The transforming growth factor-B superfamily of receptors. Cytokine Growth Factor Rev 2004;15:1-11.

  9. Kondou H, Mushiake S, Etani Y, Moyoshi Y, Michigami T, Ozono K.A blocking peptide for transforming growth factor-B I activation prevents hepatic fibrosis

  10. Susumu I, Fumiko 1, Goumans M, Dijke T. Signaling of transforming growth factor-B family members through Smad proteins. Eur J Biochem 2000;267:6954-6967.

  11. Heldin CH, Miyazono J, Dijke P.TGF-/3 signaling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.

  12. Roberts A.TGF-/3 signaling from receptors to the nucleus, Microbes Infect 1999;1:1265-1273.

  13. Derynck R, Zhang Y. Smad-dependent and smad-independent pathways in TGF-/3 family signaling. Nature 2003;425:577-584.

  14. 15.Whitman M. Feedback from inhibitory SMADs. Nature 1997;389:549-551.

  15. Dijke Pt, Miyazono K, CH H. Signalling inputs converge on nuclear effectors in TGF-/3 signaling. Trends Biochem Sci 2000;25:64-70.

  16. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanism ofTGF-/3 signaling in regulation of cell growth and differentiation. Immunol Lett 2002;82:85-91.

  17. Lijnen P, Petrov V, Fagard R. Association between transforming growth factor-B and hypertension. Am J Hypertens 2003;16:604-611.

  18. 19.Armendáriz-Borunda J, LeGros L, Campollo O, Panduro A, Rincón A. Antisense S-oligodeoxynucleotides down-regulate TGFB-production by Kupffer cells from CCL4-injured rat livers. Biochim Biophys Acta 1997;1353:241-252.

  19. Delgado-Rizo V, Salazar A, Panduro A,Armendáriz-Borunda J. Treatment with anti-tumor growth factor B antibodies influences an altered pattern of cytokines gene expression in injured rat liver. Biochim Biophys Acta 1998; vol 1442(I):20-27.

  20. GressnerA,Weiskirchen R, Breitkopf K, Dooley S. Roles ofTGF-/3 in hepatic fibrosis. Front Biosci 2002;7:793-807.

  21. Okuno M,Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-/3. Gastroenterology 2001;120:1781-1800.

  22. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said H, Lorenzen J

  23. 24.Arias M, Sauer-Lehnen S,Treptau J,Janoschek N,Theuerkauf I, Buettner R et

  24. 25.YataY, Gotwals P, KoteianskyV, Rockey D. Dose-dependent inhibition of hepatic fibrosis in mice by aTGF-/3 soluble receptor: Implications for antifibrotic therapy. Hepatology 2002;35:1022-1030.

  25. George J, Roulot D, KotelianskyV,Vissell D.

  26. Isaka Y,Akagi Y,Ando Y, Tsujie M, Sudo T, Ohno N

  27. Huang X, Lee C. From TGF-/3 to cancer therapy. Curr Drug Targets 2003;4:243-250.

  28. Siegel P, Massague J. Cytostatic and apoptotic actions ofTGF-/3 in homeostasis and cancer. Nature Rev Cancer 2003;3:807-817.

  29. Ignotz R, Honeyman T.TGF-/3 signaling in A549 lung carcinoma cells: Lipid second messengers. J Cell Biochem 2000;78:588-594.

  30. Duda D, Sunamura M, Lefler L, Furukawa T,Yokoyama T,Yatsuoka T et

  31. Moira K. Genetic factors in idiopathic pulmonary fibrosis: Transforming growth factor-B implicated at last. Am J Respir Crit Care Med 2003;168:410-411.

  32. Warshamana GDP, Fisher K, Liu J, Sime P, Brody A.Titration of non-replicating adenovirus as a vector for transducing active TGF-/3l gene expression causing inflammation and fibrigenesis in the lungs of C57BL/ 6 mice. Inc J Exp Pathol 2002;83:183-201.

  33. Kenyon N,Ward R, McGrew G, Last J.TGF-/31 causes airway fibrosis and increased collagen I and Ill mRNA in mice. Thorax 2003;58:772-777.

  34. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Mlyazono K et

  35. Rabbani Z,Anscher M, Zhang X, Chen L, Samulski T, Li C et al. Soluble TGF-/3 type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys 2003;57:563-572.

  36. Chen S, Jim B, Ziyadeh F. Diabetic nephropathy and transforming growth factor B:Transforming our view of glomerulosclerosis and fibrosis build-up. Sem Nephrol 2003;23:532-543.

  37. Daniel C,TakabatakeY, Mizui M, IsakaY, Kawashi H, Ruppecht H et 2003;163: 1185-1192.

  38. Sato M, MuragakiY, Saika S, Roberts A, Ooshima A.Targeted disruption of TGF-beta I /Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.J Clin Invest 2003;1 12:1486-1494.

  39. Mallat Z, GojovaA, Marchiol-Fournigault C, Esposio B, Kamaté C, Merval R et

  40. Robertson A, Rudling M, Zhu X, Gorelik L, Flavell R, Hansson G. Disruption ofTGF-/3 signaling in T cells accelerates atherosclerosis. J Clin Invest 2003;112:1342-1350.

  41. in vivo. J Hepatol 2003;39:742-748.et al. Smad-7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178-191.al.Adenoviral expression of a transforming growth factor B I antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterology 2003;3:1-12.In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor:A potential new therapy for hepatic fibrosis. Proc Natl Acad Scil USA 1999;96:12719-12724.et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999;55:465-475.al. Restoration of Smad4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 2003;22:6857-6864.al. Transient gene transfer and expression of Smad 7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999;104:5-11.al. Antisense oligonucleotides against thrombospondin- I inhibit activation ofTGF-/3 fibrotic renal disease in the rat in vive. Am J Patholal. Inhibiton of transforming growth factor B signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001;89:930-934.

  42. Blobe G, Schiemman W, Lodish H. Role of transforming growth factor B in human disease. N Engl J Med 2000;4:1350-1358.

  43. Zhu H, Burgess A. Regulation of transforming growth factor B signaling. Mol Cell Biol Res Community 2001;4:321-330.

  44. Miyazono K. Positive and negative regulation ofTGF/3 signaling.J Cell Sci 2000;113:1101-1109.

  45. Peralta-Zaragoza O, Lagunas-Martínez A, Madrid-Marina V. Transforming growth factor beta-1: Structure, function, and regulation mechanisms in cancer. Salud Publica Mex 2001;43:340-351.salud pública de méxico/vol.46, no.4, julio-agosto de 2004

  46. Border W, Noble N.TGF-/3. Sci Am Sci Med 1995;2:68-77.

  47. Bissell M, Roulot D, George J.Transforming growth factor and the liver. Hepatology 2001;34:859-867.

  48. Hernández-Cañaveral I, González J, López-Casillas F,Armendáriz-Borunda J. Amplified expression of dominant-negative transforming growth factor-beta type 11 receptor inhibits collagen type 1 production via reduced Smad-3 activity.J Gastroenterol Hepatol 2004;19:380-387.

  49. Caestecker M.The transforming growth factor-B superfamily of receptors. Cytokine Growth Factor Rev 2004;15:1-11.

  50. Kondou H, Mushiake S, Etani Y, Moyoshi Y, Michigami T, Ozono K.A blocking peptide for transforming growth factor-B I activation prevents hepatic fibrosis

  51. Susumu I, Fumiko I, Goumans M, Dijke T. Signaling of transforming growth factor-B family members through Smad proteins. Eur J Biochem 2000;267:6954-6967.

  52. Heldin CH, Miyazono J, Dijke P.TGF-/3 signaling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.

  53. Roberts A.TGF-/3 signaling from receptors to the nucleus, Microbes Infect 1999;1:1265-1273.

  54. Derynck R, Zhang Y. Smad-dependent and smad-independent pathways in TGF-/3 family signaling. Nature 2003;425:577-584.

  55. 15.Whitman M. Feedback from inhibitory SMADs. Nature 1997;389:549-551.

  56. Dijke Pt, Miyazono K, CH H. Signalling inputs converge on nuclear effectors in TGF-/3 signaling. Trends Biochem Sci 2000;25:64-70.

  57. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanism ofTGF-/3 signaling in regulation of cell growth and differentiation. Immunol Lett 2002;82:85-91.

  58. Lijnen P, Petrov V, Fagard R. Association between transforming growth factor-B and hypertension. Am J Hypertens 2003;16:604-611.

  59. 19.Armendáriz-Borunda J, LeGros L, Campollo O, Panduro A, Rincón A. Antisense S-oligodeoxynucleotides down-regulate TGFB-production by Kupffer cells from CCL4-injured rat livers. Biochim Biophys Acta 1997;1353:241-252.

  60. Delgado-Rizo V, Salazar A, Panduro A,Armendáriz-Borunda J. Treatment with anti-tumor growth factor B antibodies influences an altered pattern of cytokines gene expression in injured rat liver. Biochim Biophys Acta 1998; vol 1442(I):20-27.

  61. GressnerA,Weiskirchen R, Breitkopf K, Dooley S. Roles ofTGF-/3 in hepatic fibrosis. Front Biosci 2002;7:793-807.

  62. Okuno M,Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-/3. Gastroenterology 2001;120:1781-1800.

  63. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said H, Lorenzen J

  64. 24.Arias M, Sauer-Lehnen S,Treptau J,Janoschek N,Theuerkauf I, Buettner R et

  65. 25.YataY, Gotwals P, KoteianskyV, Rockey D. Dose-dependent inhibition of hepatic fibrosis in mice by aTGF-/3 soluble receptor: Implications for antifibrotic therapy. Hepatology 2002;35:1022-1030.

  66. George J, Roulot D, KotelianskyV,Vissell D.

  67. Isaka Y,Akagi Y,Ando Y, Tsujie M, Sudo T, Ohno N

  68. Huang X, Lee C. From TGF-/3 to cancer therapy. Curr Drug Targets 2003;4:243-250.

  69. Siegel P, Massague J. Cytostatic and apoptotic actions ofTGF-/3 in homeostasis and cancer. Nature Rev Cancer 2003;3:807-817.

  70. Ignotz R, Honeyman T.TGF-/3 signaling in A549 lung carcinoma cells: Lipid second messengers. J Cell Biochem 2000;78:588-594.

  71. Duda D, Sunamura M, Lefler L, Furukawa T,Yokoyama T,Yatsuoka T et

  72. Moira K. Genetic factors in idiopathic pulmonary fibrosis: Transforming growth factor-B implicated at last. Am J Respir Crit Care Med 2003;168:410-411.

  73. Warshamana GDP, Fisher K, Liu J, Sime P, Brody A.Titration of non-replicating adenovirus as a vector for transducing active TGF-/3l gene expression causing inflammation and fibrigenesis in the lungs of C57BL/6 mice. Inc J Exp Pathol 2002;83:183-201.

  74. Kenyon N,Ward R, McGrew G, Last J.TGF-/31 causes airway fibrosis and increased collagen I and Ill mRNA in mice. Thorax 2003;58:772-777.

  75. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Mlyazono K et

  76. Rabbani Z,Anscher M, Zhang X, Chen L, Samulski T, Li C et al. Soluble TGF-/3 type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys 2003;57:563-572.

  77. Chen S, Jim B, Ziyadeh F. Diabetic nephropathy and transforming growth factor B:Transforming our view of glomerulosclerosis and fibrosis build-up. Sem Nephrol 2003;23:532-543.

  78. Daniel C,TakabatakeY, Mizui M, IsakaY, Kawashi H, Ruppecht H et 2003;163: 1185-1192.

  79. Sato M, MuragakiY, Saika S, Roberts A, Ooshima A.Targeted disruption of TGF-beta I/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.J Clin Invest 2003;1 12:1486-1494.

  80. Mallat Z, GojovaA, Marchiol-Fournigault C, Esposio B, Kamaté C, Merval R et

  81. Robertson A, Rudling M, Zhu X, Gorelik L, Flavell R, Hansson G. Disruption ofTGF-/3 signaling in T cells accelerates atherosclerosis. J Clin Invest 2003;112:1342-1350.




2020     |     www.medigraphic.com